長春高新(000661.SZ)：子公司擬引進上海蓋浦生物一種白介素-2突變體專利技術實施許可權利
格隆匯8月13日丨長春高新(000661.SZ)公佈，公司第十屆董事會第二次會議決議，審議通過《關於公司子公司金賽藥業與上海蓋浦生物科技有限公司就重組白介素-2突變體技術引進項目的議案》 ，
公司子公司金賽藥業擬引進上海蓋浦生物科技有限公司(“上海蓋浦生物”)一種白介素-2突變體專利技術實施許可權利。
項目合作背景：細胞免疫治療是近年來一種有效治療腫瘤或自身免疫疾病的方法，白介素-2是趨化因子家族的一種多向性作用的細胞因子，對機體的免疫應答和抗病毒感染等有重要作用。本項目重組人白介素-2 突變體目前已經確定臨牀研究候選化合物，上海蓋浦生物申請了相關發明專利《一種增殖免疫細胞的突變體蛋白》。同時以上述專利為優先權，於 2020 年 5 月 14 日進行了 PCT 專利申請，將在PCT申請國家階段進入中國、美國、歐盟、日本、韓國、俄羅斯、巴西、加拿大、澳大利亞、新加坡等。金賽藥業擬有償獲得其在全球範圍內相關權利。
此次合作協議的主要內容：上海蓋浦生物向金賽藥業許可上述申請專利使用權，以商業化為目的在全球範圍內合法地、獨家地、全適應症領域地、無限期地、不受限制地使用該項技術開發、生產、製造、使用、銷售、許諾銷售、進口專利技術開發重組人白介素-2突變體白蛋白融合蛋白分子藥物、以及開發另一個白介素-2 突變體分子藥物。金賽藥業有權在全球範圍內針對授權中技術和專利向第三方進行分許可，但應與上海蓋浦生物一併與第三方簽訂相關協議後轉讓或授權方可生效。
金賽藥業將按照合作協議支付上海蓋浦生物相應款項，具體包括：技術許可費用、專利維護費等里程碑付款共14740萬元人民幣(其中首付款為260萬元人民幣)，並支付銷售提成。
從公司自身整體戰略佈局上看，此次擬引進的重組白介素-2 突變體技術是腫瘤免疫領域中具有市場潛力的臨牀前大分子產品，目前金賽腫瘤領域的佈局涵蓋激素瘤、血液瘤和實體瘤，引進該項目將進一步完善金賽藥業腫瘤產品線。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
